BOLT Key Statistics, Chart & Performance
The current stock price of BOLT is 5.88 USD. In the past month the price increased by 8.49%. In the past year, price decreased by -45.42%.
BOLT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About BOLT
Company Profile
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is headquartered in Redwood City, California and currently employs 52 full-time employees. The company went IPO on 2021-02-05. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The firm is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Company Info
BOLT BIOTHERAPEUTICS INC
900 Chesapeake Drive
Redwood City CALIFORNIA 94063 US
CEO: Randall C. Schatzman
Employees: 52
Phone: 16506659295
BOLT BIOTHERAPEUTICS INC / BOLT FAQ
What does BOLT BIOTHERAPEUTICS INC do?
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is headquartered in Redwood City, California and currently employs 52 full-time employees. The company went IPO on 2021-02-05. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The firm is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Can you provide the latest stock price for BOLT BIOTHERAPEUTICS INC?
The current stock price of BOLT is 5.88 USD. The price increased by 3.89% in the last trading session.
Does BOLT stock pay dividends?
BOLT does not pay a dividend.
How is the ChartMill rating for BOLT BIOTHERAPEUTICS INC?
BOLT has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is BOLT BIOTHERAPEUTICS INC (BOLT) expected to grow?
The Revenue of BOLT BIOTHERAPEUTICS INC (BOLT) is expected to decline by -39.51% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for BOLT stock?
BOLT BIOTHERAPEUTICS INC (BOLT) currently has 52 employees.
What is the next earnings date for BOLT stock?
BOLT BIOTHERAPEUTICS INC (BOLT) will report earnings on 2026-03-23, after the market close.
BOLT Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to BOLT. When comparing the yearly performance of all stocks, BOLT is a bad performer in the overall market: 86.66% of all stocks are doing better.
BOLT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BOLT. BOLT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
BOLT Financial Highlights
Over the last trailing twelve months BOLT reported a non-GAAP Earnings per Share(EPS) of -21.58. The EPS increased by 32.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.61% | ||
| ROE | -132.96% | ||
| Debt/Equity | 0 |
BOLT Forecast & Estimates
11 analysts have analysed BOLT and the average price target is 27.29 USD. This implies a price increase of 364.03% is expected in the next year compared to the current price of 5.88.
For the next year, analysts expect an EPS growth of 28.78% and a revenue growth -39.51% for BOLT